Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Travere Therapeutics, Inc. (TVTX)
USD55.98
-0.31 (-0.55%)
US NASDAQ Healthcare Biotechnology
Address
3611 Valley Centre Drive 92130
San Diego, CA, US
San Diego, CA, US
CEO
Eric Dube
Website
travere.com
IPO
2012-11-08
CIK 1438533 ISIN US89422G1076
Description
Travere Therapeutics, Inc., a biopharmaceutical firm headquartered in San Diego, California, was founded in 2008 with a mission to discover, develop, commercialize, and deliver treatments for rare diseases. The company adopted its current name in November 2020, previously operating as Retrophin, Inc. Its current product offerings include Chenodal, an orally administered synthetic form of chenodeoxycholic acid, used to dissolve radiolucent gallstones. Another key product is Cholbam, a cholic acid capsule prescribed for both children and adults suffering from bile acid synthesis disorders stemming from single enzyme defects, and as an auxiliary treatment for peroxisomal disorders. Additionally, Thiola and Thiola EC, tiopronin tablets, are available for managing homozygous cystinuria. In its development pipeline, Travere is advancing several therapeutic candidates. Sparsentan is currently in Phase III clinical trials, being investigated for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Also under development is TVT-058, a pioneering investigational human enzyme replacement candidate, which is undergoing Phase I/II clinical trials for classical homocystinuria. The company actively engages in strategic partnerships, holding a cooperative research and development agreement with the National Institutes of Health's National Center for Advancing Translational Sciences. It also collaborates with patient advocacy groups such as CDG Care and the Alagille Syndrome Alliance, collectively working towards identifying potential small molecule therapies for NGLY1 deficiency and Alagille syndrome.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD55.98
-0.31 (-0.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.11
Float Shares
90.72M
Free Float %
98.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.54% | -5.87% | +47.93% | +40.00% | +17.47% | +12.12% | +98.89% | +171.31% | +120.94% | +182.96% | +2,756.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
55.98
Low
49.00
-12.5%
Consensus
51.50
-8.0%
Median
51.50
-8.0%
High
54.00
-3.5%
Ratings Trend (MoM)
93% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 12 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
51.50
-8.0%
|
| Last Quarter | 2 |
51.50
-8.0%
|
| Last Year | 4 |
46.75
-16.5%
|
| All Time | 19 |
25.16
-55.1%
|
Quality scores
Altman Z-Score
2.75
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+110.5% ★ Q1'26: +55.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+86.3% ★ Q1'26: +14.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-0.7% Q1'26: -49.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-7.9% Q1'26: -29.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-31.9% Q1'26: -91.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.1% Q1'26: +4.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×14.80× Q1'26: -7.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 8 EPS Ana. |
Dec 2027 11 Rev. Ana. 8 EPS Ana. |
Dec 2028 9 Rev. Ana. 5 EPS Ana. |
Dec 2029 4 Rev. Ana. 1 EPS Ana. |
Dec 2030 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
99.89M
est: 98.90M (+1.0%)
|
133.59M
est: 132.24M (+1.0%)
|
154.94M
est: 154.47M (+0.3%)
|
164.25M
est: 164.99M (-0.4%)
|
175.34M
est: 174.68M (+0.4%)
|
198.32M
est: 198.95M (-0.3%)
|
131.84M
est: 225.72M (-41.6%)
|
109.46M
est: 208.36M (-47.5%)
|
145.24M
est: 177.64M (-18.2%)
|
233.18M
est: 230.97M (+1.0%)
|
490.73M
est: 499.28M (-1.7%)
|
699.59M
644.71M – 742.85M
+40.1% YoY
|
974.82M
903.55M – 1.11B
+39.3% YoY
|
1.18B
1.18B – 1.18B
+21.1% YoY
|
1.45B
1.24B – 1.78B
+22.6% YoY
|
1.69B
1.44B – 2.08B
+16.4% YoY
|
| EBITDA |
129.46M
est: -93.60M (+238.3%)
|
-38.79M
est: -125.15M (+69.0%)
|
-38.67M
est: -146.19M (+73.5%)
|
-73.39M
est: -156.14M (+53.0%)
|
-107.21M
est: -165.31M (+35.1%)
|
-145.16M
est: -188.28M (+22.9%)
|
-184.46M
est: -103.93M (-77.5%)
|
-299.42M
est: -133.25M (-124.7%)
|
-326.25M
est: -140.51M (-132.2%)
|
-265.77M
est: -182.69M (-45.5%)
|
22.22M
est: -394.90M (+105.6%)
|
-553.34M
-587.56M – -509.93M
-40.1% YoY
|
-771.03M
-879.68M – -714.66M
-39.3% YoY
|
-933.85M
-933.85M – -933.85M
-21.1% YoY
|
-1.15B
-1.41B – -979.49M
-22.6% YoY
|
-1.33B
-1.64B – -1.14B
-16.4% YoY
|
| EBIT |
113.22M
est: -96.05M (+217.9%)
|
-52.85M
est: -128.42M (+58.8%)
|
-53.94M
est: -150.02M (+64.0%)
|
-92.06M
est: -160.23M (+42.5%)
|
-127.62M
est: -169.64M (+24.8%)
|
-169.74M
est: -193.21M (+12.1%)
|
-197.20M
est: -128.67M (-53.3%)
|
-320.14M
est: -159.16M (-101.1%)
|
-364.78M
est: -144.90M (-151.7%)
|
-309.33M
est: -188.40M (-64.2%)
|
-38.53M
est: -407.26M (+90.5%)
|
-570.66M
-605.95M – -525.89M
-40.1% YoY
|
-795.16M
-907.21M – -737.03M
-39.3% YoY
|
-963.08M
-963.08M – -963.08M
-21.1% YoY
|
-1.18B
-1.45B – -1.01B
-22.6% YoY
|
-1.38B
-1.69B – -1.18B
-16.4% YoY
|
| Net Income |
117.24M
est: 240.61M (-51.3%)
|
-47.90M
est: -104.40M (+54.1%)
|
-59.73M
est: -99.01M (+39.7%)
|
-102.68M
est: -144.63M (+29.0%)
|
-146.43M
est: -223.71M (+34.5%)
|
-169.43M
est: -114.05M (-48.6%)
|
-180.09M
est: -142.95M (-26.0%)
|
-278.48M
est: -307.44M (+9.4%)
|
-111.40M
est: -383.45M (+70.9%)
|
-321.55M
est: -324.92M (+1.0%)
|
-25.55M
est: -45.64M (+44.0%)
|
29.65M
-51.76M – 138.03M
+165.0% YoY
|
242.17M
-24.15M – 558.17M
+716.6% YoY
|
328.91M
198.38M – 500.87M
+35.8% YoY
|
380.04M
308.51M – 494.17M
+15.5% YoY
|
475.20M
385.76M – 617.91M
+25.0% YoY
|
| SGA |
79.54M
est: 126.75M (-37.2%)
|
98.02M
est: 169.48M (-42.2%)
|
103.96M
est: 197.97M (-47.5%)
|
103.65M
est: 211.45M (-51.0%)
|
128.95M
est: 223.87M (-42.4%)
|
135.80M
est: 254.98M (-46.7%)
|
126.28M
est: 122.85M (+2.8%)
|
197.52M
est: 144.87M (+36.3%)
|
265.54M
est: 227.76M (+16.6%)
|
264.12M
est: 296.13M (-10.8%)
|
337.20M
est: 640.13M (-47.3%)
|
896.95M
826.59M – 952.42M
+40.1% YoY
|
1.25B
1.16B – 1.43B
+39.3% YoY
|
1.51B
1.51B – 1.51B
+21.1% YoY
|
1.86B
1.59B – 2.29B
+22.6% YoY
|
2.16B
1.85B – 2.66B
+16.4% YoY
|
| EPS |
3.49
est: 3.05 (+14.4%)
|
-1.29
est: -1.32 (+2.5%)
|
-1.54
est: -1.26 (-22.7%)
|
-2.54
est: -1.83 (-38.5%)
|
-3.46
est: -2.84 (-22.0%)
|
-3.56
est: -1.45 (-146.2%)
|
-3.01
est: -3.01 (+0.1%)
|
-4.37
est: -4.48 (+2.4%)
|
-1.50
est: -4.99 (+69.9%)
|
-4.08
est: -3.65 (-11.9%)
|
-0.56
est: -0.34 (-67.0%)
|
0.34
-0.58 – 1.55
+200.0% YoY
|
2.47
-0.27 – 6.26
+636.1% YoY
|
3.25
2.22 – 5.61
+31.6% YoY
|
4.26
3.46 – 5.54
+31.1% YoY
|
5.33
4.32 – 6.93
+25.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Wells Fargo | Overweight | Overweight | Maintain |
| 2026-05-05 | Wedbush | Outperform | Outperform | Maintain |
| 2026-04-24 | Guggenheim | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
65.00M
OE per share TTM
0.70
Owner's Yield
1.63%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
9.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
49
Total invested
159.54M
Insider transactions (90d)
2
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 4.83M | 9.50% | 4.66M | — | 4.83M | — | HC | Delaware | 2021-02-01 | ↗ |
| 2 | GOLDMAN SACHS & CO. LLC | 4.60M | 7.50% | — | 4.60M | — | 4.60M | BD, IA, OO | Delaware | 2022-02-01 | ↗ |
| 3 | THE GOLDMAN SACHS GROUP, INC. | 4.60M | 7.50% | — | 4.60M | — | 4.60M | HC, CO | Delaware | 2022-02-01 | ↗ |
| 4 | Adage Capital Advisors, L.L.C. | 4.42M | 5.94% | — | 4.42M | — | — | OO | Delaware | 2023-03-13 | ↗ |
| 5 | Adage Capital Partners GP, L.L.C. | 4.42M | 5.94% | — | 4.42M | — | — | OO | Delaware | 2023-03-13 | ↗ |
| 6 | Adage Capital Partners, L.P. | 4.42M | 5.94% | — | 4.42M | — | — | PN | Delaware | 2023-03-13 | ↗ |
| 7 | Phillip Gross | 4.42M | 5.94% | — | 4.42M | — | — | IN | Delaware | 2023-03-13 | ↗ |
| 8 | Robert Atchinson | 4.42M | 5.94% | — | 4.42M | — | — | IN | Delaware | 2023-03-13 | ↗ |
| 9 | Rock Springs Capital Management LP | 4.41M | 5.79% | — | 4.41M | — | 4.41M | IA | Delaware | 2024-05-01 | ↗ |
| 10 | Woodline Partners LP | 4.34M | 5.70% | 4.34M | — | 4.34M | — | IA | Delaware | 2024-11-14 | ↗ |
| 11 | STATE STREET CORPORATION | 4.22M | 6.58% | — | 4.10M | — | 4.22M | HC | — | 2023-02-06 | ↗ |
| 12 | Morgan Stanley | 4.15M | 5.50% | 13.00 | — | 13.00 | 4.15M | HC, CO | Delaware. | 2024-02-09 | ↗ |
| 13 | Armistice Capital, LLC | 4.08M | 6.70% | — | 4.08M | — | 4.08M | IA, OO | — | 2022-02-14 | ↗ |
| 14 | Steven Boyd | 4.08M | 6.70% | — | 4.08M | — | 4.08M | HC, IN | — | 2022-02-14 | ↗ |
| 15 | EIN #00-0000000 | 4.02M | 6.60% | — | 4.02M | — | 4.02M | IA, HC | Jersey, Channel Islands | 2022-02-10 | ↗ |
| 16 | 10. | 3.77M | 6.15% | — | — | — | — | HC | — | 2022-02-14 | ↗ |
| 17 | 10 | 3.49M | 6.80% | — | 3.49M | — | 3.49M | IA | United States of America | 2021-02-16 | ↗ |
| 18 | David Kroin | 3.44M | 5.41% | — | 3.44M | — | — | HC, IN | Delaware | 2022-05-16 | ↗ |
| 19 | Deep Track Biotechnology Master Fund, Ltd. | 3.44M | 5.41% | — | 3.44M | — | — | CO | Delaware | 2022-05-16 | ↗ |
| 20 | Deep Track Capital, LP | 3.44M | 5.41% | — | 3.44M | — | — | IA, OO | Delaware | 2022-05-16 | ↗ |
| 21 | Israel A. Englander | 727.2K | 1.40% | — | 727.2K | — | 727.2K | IN | — | 2021-02-11 | ↗ |
| 22 | Millennium Group Management LLC | 727.2K | 1.40% | — | 727.2K | — | 727.2K | OO | — | 2021-02-11 | ↗ |
| 23 | Millennium Management LLC | 727.2K | 1.40% | — | 727.2K | — | 727.2K | OO | — | 2021-02-11 | ↗ |
| 24 | Integrated Core Strategies (US) LLC | 708.8K | 1.40% | — | 708.8K | — | 708.8K | OO | — | 2021-02-11 | ↗ |
| 25 | Millennium International Management LP | 18.4K | 0.00% | — | 18.4K | — | 18.4K | PN | — | 2021-02-11 | ↗ |
| 26 | ICS Opportunities II LLC | 11.2K | 0.00% | — | 11.2K | — | 11.2K | OO | — | 2021-02-11 | ↗ |
| 27 | ICS Opportunities, Ltd. | 6.5K | 0.00% | — | 6.5K | — | 6.5K | CO | — | 2021-02-11 | ↗ |
| 28 | ☐ | 1.6K | 0.00% | 1.6K | — | 1.6K | — | CO | — | 2022-02-14 | ↗ |
| 29 | Integrated Assets, Ltd. | 731.00 | 0.00% | — | 731.00 | — | 731.00 | CO | — | 2021-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
49
-250 vs prev Q
New positions
10
Closed positions
243
Increased
25
Reduced
15
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 3.77M +3.8M (+100.0%) | 144.19B +144.2B (+100.0%) | 4.23% +4.229 pp | 0.22% +0.218 pp | USD38.21 +0.0% | 1 qtrs NEW |
| 2 | — | 110.0K +110.0K (+100.0%) | 4.20B +4.2B (+100.0%) | 0.12% +0.123 pp | 1.24% +1.240 pp | USD38.21 +0.0% | 1 qtrs NEW |
| 3 | JANUS HENDERSON GROUP PLC | 10.51M -88.5K (-0.8%) | 401.72M +148.4M (+58.6%) | 11.78% -0.137 pp | 0.18% +0.064 pp | USD17.76 +115.1% | 21 qtrs — |
| 4 | FMR LLC | 9.62M +6.7M (+232.3%) | 367.50M +298.3M (+431.3%) | 10.78% +7.525 pp | 0.02% +0.015 pp | USD33.16 +15.2% | 21 qtrs — |
| 5 | BLACKROCK, INC. | 7.87M -231.1K (-2.9%) | 300.69M +107.1M (+55.3%) | 8.82% -0.288 pp | 0.01% +0.002 pp | USD14.27 +167.8% | 6 qtrs — |
| 6 | VANGUARD GROUP INC | 6.31M -304.1K (-4.6%) | 241.08M +83.0M (+52.5%) | 7.07% -0.365 pp | 0.00% +0.001 pp | USD18.91 +102.1% | 21 qtrs — |
| 7 | STATE STREET CORP | 4.76M +1.5M (+47.8%) | 181.75M +104.8M (+136.3%) | 5.33% +1.713 pp | 0.01% +0.003 pp | USD23.67 +61.4% | 20 qtrs — |
| 8 | PERCEPTIVE ADVISORS LLC | 4.28M +483.6K (+12.7%) | 163.47M +72.8M (+80.2%) | 4.79% +0.528 pp | 2.91% +0.295 pp | USD23.74 +61.0% | 3 qtrs — |
| 9 | ARMISTICE CAPITAL, LLC | 3.76M -3.0M (-44.0%) | 143.82M -16.9M (-10.5%) | 4.22% -3.342 pp | 1.71% -0.673 pp | USD19.90 +92.0% | 20 qtrs — |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.93M -625.0K (-17.6%) | 111.84M +26.9M (+31.7%) | 3.28% -0.713 pp | 0.17% +0.035 pp | USD17.74 +115.4% | 9 qtrs — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 2.25M +494.7K (+28.2%) | 85.85M +44.0M (+105.0%) | 2.52% +0.548 pp | 0.13% +0.078 pp | USD21.79 +75.4% | 21 qtrs — |
| 12 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 2.21M +45.5K (+2.1%) | 84.46M +32.7M (+63.2%) | 2.48% +0.043 pp | 4.33% +1.308 pp | USD15.51 +146.4% | 21 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 2.14M +5.5K (+0.3%) | 81.92M +30.8M (+60.3%) | 2.40% -0.002 pp | 0.01% +0.002 pp | USD21.25 +79.8% | 21 qtrs — |
| 14 | GOLDMAN SACHS GROUP INC | 1.87M +594.3K (+46.7%) | 71.38M +40.9M (+134.5%) | 2.09% +0.662 pp | 0.01% +0.005 pp | USD23.27 +64.2% | 21 qtrs — |
| 15 | BANK OF AMERICA CORP /DE/ | 1.85M +451.4K (+32.3%) | 70.70M +37.3M (+111.5%) | 2.07% +0.501 pp | 0.01% +0.003 pp | USD21.31 +79.3% | 21 qtrs — |
| 16 | STEPHENS INVESTMENT MANAGEMENT GROUP LLC | 1.72M +122.0K (+7.6%) | 65.78M +27.6M (+72.1%) | 1.93% +0.131 pp | 0.86% +0.361 pp | USD24.91 +53.4% | 2 qtrs — |
| 17 | EMERALD ADVISERS, LLC | 1.59M -552.6K (-25.7%) | 60.91M +9.6M (+18.7%) | 1.79% -0.627 pp | 1.88% +0.232 pp | USD11.99 +218.7% | 11 qtrs — |
| 18 | MORGAN STANLEY | 1.42M +298.9K (+26.8%) | 54.10M +27.4M (+102.6%) | 1.59% +0.331 pp | 0.00% +0.002 pp | USD18.02 +112.0% | 21 qtrs — |
| 19 | EVERSEPT PARTNERS, LP | 1.17M -242.2K (-17.1%) | 44.90M +11.0M (+32.5%) | 1.32% -0.277 pp | 2.26% -0.072 pp | USD13.62 +180.5% | 8 qtrs — |
| 20 | TWO SIGMA INVESTMENTS, LP | 1.16M +227.8K (+24.5%) | 44.20M +22.0M (+99.1%) | 1.30% +0.252 pp | 0.06% +0.029 pp | USD18.69 +104.4% | 17 qtrs — |
| 21 | D. E. SHAW & CO., INC. | 1.09M +431.3K (+65.0%) | 41.82M +26.0M (+163.8%) | 1.23% +0.481 pp | 0.02% +0.014 pp | USD24.70 +54.7% | 21 qtrs — |
| 22 | POINT72 ASSET MANAGEMENT, L.P. | 1.02M +1.0M (+100.0%) | 38.91M +38.9M (+100.0%) | 1.14% +1.141 pp | 0.04% +0.044 pp | USD38.21 +0.0% | 1 qtrs NEW |
| 23 | NUVEEN, LLC | 993.6K -85.1K (-7.9%) | 37.97M +12.2M (+47.3%) | 1.11% -0.099 pp | 0.01% +0.003 pp | USD17.92 +113.2% | 4 qtrs — |
| 24 | EMERALD MUTUAL FUND ADVISERS TRUST | 948.5K -252.5K (-21.0%) | 36.24M +7.5M (+26.3%) | 1.06% -0.287 pp | 1.77% +0.283 pp | USD12.24 +212.2% | 11 qtrs — |
| 25 | DRIEHAUS CAPITAL MANAGEMENT LLC | 901.4K +193.9K (+27.4%) | 34.44M +17.5M (+103.7%) | 1.01% +0.215 pp | 0.23% +0.113 pp | USD26.98 +41.6% | 6 qtrs — |
| 26 | HUDSON BAY CAPITAL MANAGEMENT LP | 900.3K +584.0K (+184.6%) | 34.40M +26.8M (+355.1%) | 1.01% +0.653 pp | 0.11% +0.088 pp | USD33.18 +15.2% | 2 qtrs — |
| 27 | DEUTSCHE BANK AG\ | 881.7K -717.6K (-44.9%) | 33.69M -4.5M (-11.9%) | 0.99% -0.810 pp | 0.01% -0.002 pp | USD19.76 +93.4% | 21 qtrs — |
| 28 | FIERA CAPITAL CORP | 874.1K +874.1K (+100.0%) | 33.40M +33.4M (+100.0%) | 0.98% +0.980 pp | 0.11% +0.106 pp | USD38.21 +0.0% | 1 qtrs NEW |
| 29 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 867.6K -16.1K (-1.8%) | 33.15M +12.0M (+57.0%) | 0.97% -0.021 pp | 0.12% +0.046 pp | USD16.66 +129.4% | 6 qtrs — |
| 30 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 808.2K -40.2K (-4.7%) | 30.88M +10.6M (+52.3%) | 0.91% -0.048 pp | 0.00% +0.002 pp | USD22.20 +72.1% | 21 qtrs — |
| 31 | ENSIGN PEAK ADVISORS, INC | 805.2K -47.0K (-5.5%) | 30.77M +10.4M (+51.1%) | 0.90% -0.056 pp | 0.05% +0.021 pp | USD16.61 +130.0% | 4 qtrs — |
| 32 | WELLINGTON MANAGEMENT GROUP LLP | 799.0K -402.5K (-33.5%) | 30.53M +1.8M (+6.3%) | 0.90% -0.455 pp | 0.01% +0.000 pp | USD23.71 +61.2% | 9 qtrs — |
| 33 | NORTHERN TRUST CORP | 761.5K -70.6K (-8.5%) | 29.10M +9.2M (+46.3%) | 0.85% -0.082 pp | 0.00% +0.001 pp | USD24.19 +58.0% | 21 qtrs — |
| 34 | TWO SIGMA ADVISERS, LP | 725.5K +28.8K (+4.1%) | 27.72M +11.1M (+66.5%) | 0.81% +0.030 pp | 0.05% +0.021 pp | USD18.91 +102.1% | 17 qtrs — |
| 35 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 718.4K +298.0K (+70.9%) | 27.45M +17.4M (+173.2%) | 0.81% +0.333 pp | 0.00% +0.002 pp | USD25.33 +50.8% | 21 qtrs — |
| 36 | TANG CAPITAL MANAGEMENT LLC | 700.0K +— (+0.0%) | 26.75M +10.0M (+59.9%) | 0.78% -0.003 pp | 1.32% +0.677 pp | USD14.80 +158.2% | 3 qtrs — |
| 37 | CAPTION MANAGEMENT, LLC | 666.4K +91.0K (+15.8%) | 25.46M +11.7M (+85.2%) | 0.75% +0.100 pp | 0.17% +0.067 pp | USD22.69 +68.4% | 6 qtrs — |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 665.8K +100.2K (+17.7%) | 25.44M +11.9M (+88.2%) | 0.75% +0.110 pp | 0.01% +0.004 pp | USD24.24 +57.6% | 5 qtrs — |
| 39 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 623.4K -234.5K (-27.3%) | 23.82M +3.3M (+16.2%) | 0.70% -0.266 pp | 0.06% -0.002 pp | USD18.39 +107.8% | 18 qtrs — |
| 40 | PANAGORA ASSET MANAGEMENT INC | 587.4K +17.7K (+3.1%) | 22.44M +8.8M (+64.8%) | 0.66% +0.018 pp | 0.08% +0.025 pp | USD16.38 +133.3% | 13 qtrs — |
| 41 | PICTET ASSET MANAGEMENT HOLDING SA | 534.6K -149.8K (-21.9%) | 20.78M +4.3M (+26.3%) | 0.60% -0.170 pp | 0.02% +0.004 pp | USD10.88 +251.2% | 10 qtrs — |
| 42 | LEGAL & GENERAL GROUP PLC | 536.9K +16.3K (+3.1%) | 20.52M +8.1M (+64.9%) | 0.60% +0.016 pp | 0.00% +0.002 pp | USD18.32 +108.6% | 21 qtrs — |
| 43 | ABRDN PLC | 518.4K -449.0K (-46.4%) | 19.81M -3.3M (-14.3%) | 0.58% -0.507 pp | 0.03% -0.006 pp | USD16.81 +127.3% | 5 qtrs — |
| 44 | KYNAM CAPITAL MANAGEMENT, LP | 517.9K -431.8K (-45.5%) | 19.79M -2.9M (-12.8%) | 0.58% -0.487 pp | 1.26% -0.426 pp | USD16.21 +135.7% | 17 qtrs — |
| 45 | INVESCO LTD. | 474.1K -153.8K (-24.5%) | 18.11M +3.1M (+20.7%) | 0.53% -0.175 pp | 0.00% +0.000 pp | USD17.70 +115.9% | 21 qtrs — |
| 46 | CANDRIAM S.C.A. | 468.6K -44.1K (-8.6%) | 17.90M +5.7M (+46.1%) | 0.53% -0.051 pp | 0.09% +0.025 pp | USD17.92 +113.2% | 4 qtrs — |
| 47 | UBS GROUP AG | 422.6K -70.5K (-14.3%) | 16.15M +4.4M (+37.0%) | 0.47% -0.081 pp | 0.00% +0.001 pp | USD15.24 +150.7% | 21 qtrs — |
| 48 | ASSENAGON ASSET MANAGEMENT S.A. | 417.7K +324.4K (+347.5%) | 15.96M +13.7M (+615.4%) | 0.47% +0.363 pp | 0.02% +0.019 pp | USD32.56 +17.4% | 17 qtrs — |
| 49 | QUBE RESEARCH & TECHNOLOGIES LTD | 406.2K -165.8K (-29.0%) | 15.52M +1.9M (+13.5%) | 0.46% -0.188 pp | 0.02% +0.002 pp | USD16.27 +134.8% | 5 qtrs — |
| 50 | PRICE T ROWE ASSOCIATES INC /MD/ | 394.8K +315.4K (+397.0%) | 15.09M +13.2M (+694.5%) | 0.44% +0.353 pp | 0.00% +0.001 pp | USD33.81 +13.0% | 17 qtrs — |
| 51 | JANE STREET GROUP, LLC | 392.3K +392.3K (+100.0%) | 14.99M +15.0M (+100.0%) | 0.44% +0.440 pp | 0.00% +0.002 pp | USD38.21 +0.0% | 1 qtrs NEW |
| 52 | BARCLAYS PLC | 369.5K +200.8K (+119.0%) | 14.12M +11.8M (+498.0%) | 0.41% +0.224 pp | 0.00% +0.003 pp | USD28.80 +32.7% | 16 qtrs — |
| 53 | AQR CAPITAL MANAGEMENT LLC | 352.7K +39.3K (+12.6%) | 13.48M +6.0M (+79.9%) | 0.40% +0.043 pp | 0.01% +0.002 pp | USD19.61 +94.8% | 21 qtrs — |
| 54 | FIRST TRUST ADVISORS LP | 341.7K +169.3K (+98.2%) | 13.06M +8.9M (+216.8%) | 0.38% +0.189 pp | 0.01% +0.006 pp | USD26.40 +44.7% | 3 qtrs — |
| 55 | JPMORGAN CHASE & CO | 321.6K -172.2K (-34.9%) | 12.29M +486.1K (+4.1%) | 0.36% -0.195 pp | 0.00% +0.000 pp | USD13.00 +193.9% | 21 qtrs — |
| 56 | SQUAREPOINT OPS LLC | 319.7K +205.2K (+179.2%) | 12.21M +9.5M (+346.4%) | 0.36% +0.230 pp | 0.01% +0.010 pp | USD30.27 +26.2% | 15 qtrs — |
| 57 | AFFINITY ASSET ADVISORS, LLC | 300.0K -200.0K (-40.0%) | 11.46M -487.0K (-4.1%) | 0.34% -0.226 pp | 0.65% -0.388 pp | USD17.83 +114.3% | 5 qtrs — |
| 58 | RUSSELL INVESTMENTS GROUP, LTD. | 285.3K +63.1K (+28.4%) | 10.90M +5.6M (+105.2%) | 0.32% +0.070 pp | 0.01% +0.006 pp | USD21.00 +82.0% | 20 qtrs — |
| 59 | JACOBS LEVY EQUITY MANAGEMENT, INC | 268.9K -49.2K (-15.5%) | 10.28M +2.7M (+35.1%) | 0.30% -0.056 pp | 0.04% +0.010 pp | USD16.50 +131.6% | 21 qtrs — |
| 60 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 268.0K -60.6K (-18.4%) | 10.24M +2.4M (+30.4%) | 0.30% -0.069 pp | 0.01% +0.001 pp | USD23.90 +59.9% | 2 qtrs — |
| 61 | JENNISON ASSOCIATES LLC | 256.3K -828.0K (-76.4%) | 9.79M -16.1M (-62.2%) | 0.29% -0.932 pp | 0.01% -0.009 pp | USD19.30 +98.0% | 5 qtrs — |
| 62 | NEW YORK STATE COMMON RETIREMENT FUND | 249.6K +221.7K (+797.2%) | 9.54M +8.9M (+1,334.4%) | 0.28% +0.248 pp | 0.01% +0.012 pp | USD36.63 +4.3% | 21 qtrs — |
| 63 | CITADEL ADVISORS LLC | 244.1K +63.3K (+35.0%) | 9.33M +5.0M (+115.8%) | 0.27% +0.070 pp | 0.00% +0.001 pp | USD22.59 +69.1% | 20 qtrs — |
| 64 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 241.6K -150.5K (-38.4%) | 9.23M -139.8K (-1.5%) | 0.27% -0.170 pp | 0.25% -0.033 pp | USD14.80 +158.2% | 3 qtrs — |
| 65 | LOOMIS SAYLES & CO L P | 238.9K +238.9K (+100.0%) | 9.13M +9.1M (+100.0%) | 0.27% +0.268 pp | 0.01% +0.011 pp | USD38.21 +0.0% | 4 qtrs — |
| 66 | IMPAX ASSET MANAGEMENT GROUP PLC | 225.0K -250.0K (-52.6%) | 8.60M -2.8M (-24.3%) | 0.25% -0.282 pp | 0.05% -0.013 pp | USD16.45 +132.3% | 5 qtrs — |
| 67 | BANK OF NEW YORK MELLON CORP | 220.0K -17.2K (-7.3%) | 8.41M +2.7M (+48.3%) | 0.25% -0.020 pp | 0.00% +0.000 pp | USD22.08 +73.1% | 21 qtrs — |
| 68 | PRUDENTIAL FINANCIAL INC | 219.7K +82.1K (+59.7%) | 8.40M +5.1M (+155.3%) | 0.25% +0.092 pp | 0.01% +0.006 pp | USD22.28 +71.5% | 9 qtrs — |
| 69 | NEUBERGER BERMAN GROUP LLC | 218.0K +6.4K (+3.0%) | 8.33M +3.3M (+64.7%) | 0.24% +0.006 pp | 0.01% +0.003 pp | USD24.32 +57.1% | 2 qtrs — |
| 70 | MARSHALL WACE, LLP | 217.2K -372.9K (-63.2%) | 8.30M -5.8M (-41.2%) | 0.24% -0.420 pp | 0.01% -0.007 pp | USD14.80 +158.2% | 3 qtrs — |
| 71 | UBS ASSET MANAGEMENT AMERICAS INC | 216.0K +70.0K (+48.0%) | 8.25M +4.8M (+136.6%) | 0.24% +0.078 pp | 0.00% +0.001 pp | USD22.59 +69.1% | 21 qtrs — |
| 72 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 202.2K -11.7K (-5.5%) | 7.73M +2.6M (+51.1%) | 0.23% -0.014 pp | 0.01% +0.004 pp | USD20.11 +90.0% | 5 qtrs — |
| 73 | APIS CAPITAL ADVISORS, LLC | 186.0K +20.0K (+12.0%) | 7.11M +3.1M (+79.1%) | 0.21% +0.022 pp | 1.24% +0.362 pp | USD25.44 +50.2% | 2 qtrs — |
| 74 | KNOTT DAVID M JR | 186.0K -74.0K (-28.5%) | 7.11M +893.1K (+14.4%) | 0.21% -0.084 pp | 3.29% +0.785 pp | USD9.55 +300.1% | 10 qtrs — |
| 75 | HILLSDALE INVESTMENT MANAGEMENT INC. | 177.2K -1.2K (-0.7%) | 6.77M +2.5M (+58.8%) | 0.20% -0.002 pp | 0.19% +0.058 pp | USD15.57 +145.4% | 3 qtrs — |
| 76 | RAFFERTY ASSET MANAGEMENT, LLC | 169.2K +79.0K (+87.5%) | 6.47M +4.3M (+199.7%) | 0.19% +0.088 pp | 0.02% +0.015 pp | USD26.67 +43.3% | 21 qtrs — |
| 77 | F/M INVESTMENTS LLC | 168.4K -27.7K (-14.1%) | 6.44M +1.7M (+37.3%) | 0.19% -0.032 pp | 0.24% +0.064 pp | USD17.25 +121.5% | 5 qtrs — |
| 78 | SWISS NATIONAL BANK | 167.1K +3.5K (+2.1%) | 6.38M +2.5M (+63.3%) | 0.19% +0.003 pp | 0.00% +0.002 pp | USD24.10 +58.5% | 21 qtrs — |
| 79 | WOODLINE PARTNERS LP | 164.3K +74.9K (+83.9%) | 6.28M +4.1M (+194.0%) | 0.18% +0.084 pp | 0.02% +0.014 pp | USD24.13 +58.4% | 14 qtrs — |
| 80 | WELLS FARGO & COMPANY/MN | 158.8K +84.2K (+112.7%) | 6.07M +4.3M (+240.0%) | 0.18% +0.094 pp | 0.00% +0.001 pp | USD28.50 +34.1% | 21 qtrs — |
| 81 | ESSEX INVESTMENT MANAGEMENT CO LLC | 158.7K -3.3K (-2.0%) | 6.06M +2.2M (+56.6%) | 0.18% -0.004 pp | 0.92% +0.332 pp | USD23.90 +59.9% | 4 qtrs — |
| 82 | VOYA INVESTMENT MANAGEMENT LLC | 155.9K -39.0K (-20.0%) | 5.96M +1.3M (+27.9%) | 0.17% -0.044 pp | 0.01% +0.001 pp | USD15.25 +150.6% | 21 qtrs — |
| 83 | ALGERT GLOBAL LLC | 149.9K -3.7K (-2.4%) | 5.73M +2.1M (+56.0%) | 0.17% -0.005 pp | 0.09% +0.028 pp | USD16.64 +129.6% | 5 qtrs — |
| 84 | PDT PARTNERS, LLC | 148.7K -132.7K (-47.2%) | 5.68M -1.0M (-15.5%) | 0.17% -0.150 pp | 0.37% -0.056 pp | USD10.91 +250.2% | 12 qtrs — |
| 85 | GW&K INVESTMENT MANAGEMENT, LLC | 141.2K +23.3K (+19.8%) | 5.39M +2.6M (+91.5%) | 0.16% +0.026 pp | 0.05% +0.022 pp | USD21.80 +75.3% | 21 qtrs — |
| 86 | LISANTI CAPITAL GROWTH, LLC | 138.5K +9.0K (+6.9%) | 5.29M +2.2M (+70.9%) | 0.16% +0.010 pp | 1.25% +0.497 pp | USD24.83 +53.9% | 2 qtrs — |
| 87 | PALISADES INVESTMENT PARTNERS, LLC | 137.8K +137.8K (+100.0%) | 5.26M +5.3M (+100.0%) | 0.15% +0.154 pp | 1.99% +1.989 pp | USD38.21 +0.0% | 1 qtrs NEW |
| 88 | ENGINEERS GATE MANAGER LP | 136.6K +96.9K (+244.2%) | 5.22M +4.3M (+450.3%) | 0.15% +0.109 pp | 0.06% +0.051 pp | USD32.14 +18.9% | 7 qtrs — |
| 89 | MILLENNIUM MANAGEMENT LLC | 136.1K +2.2K (+1.6%) | 5.20M +2.0M (+62.5%) | 0.15% +0.002 pp | 0.00% +0.001 pp | USD15.51 +146.4% | 21 qtrs — |
| 90 | LORD, ABBETT & CO. LLC | 135.8K -97.0 (-0.1%) | 5.19M +1.9M (+59.8%) | 0.15% -0.001 pp | 0.02% +0.006 pp | USD17.92 +113.2% | 4 qtrs — |
| 91 | SEI INVESTMENTS CO | 133.6K +84.2K (+170.3%) | 5.10M +3.9M (+332.1%) | 0.15% +0.094 pp | 0.01% +0.004 pp | USD29.08 +31.4% | 7 qtrs — |
| 92 | ALLIANCEBERNSTEIN L.P. | 125.1K -197.0K (-61.2%) | 4.78M -2.9M (-37.9%) | 0.14% -0.222 pp | 0.00% -0.001 pp | USD19.00 +101.1% | 21 qtrs — |
| 93 | PALO ALTO INVESTORS LP | 110.7K +— (+0.0%) | 4.23M +1.6M (+59.9%) | 0.12% 0.000 pp | 0.59% +0.099 pp | USD27.14 +40.8% | 21 qtrs — |
| 94 | RHUMBLINE ADVISERS | 109.8K -20.3K (-15.6%) | 4.19M +1.1M (+35.0%) | 0.12% -0.023 pp | 0.00% +0.001 pp | USD20.09 +90.2% | 21 qtrs — |
| 95 | EAM INVESTORS, LLC | 109.4K +109.4K (+100.0%) | 4.18M +4.2M (+100.0%) | 0.12% +0.123 pp | 0.47% +0.466 pp | USD38.21 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.59
Neutral
Ratio by volume
0.69
Neutral
Buys
22
Sells
37
Shares acquired
315.5K
Shares disposed
456.6K
Cash buys
—
Cash sales
23.00
Net activity
-141,102
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Baynes Roy D. | Director | M-Exempt | A | Common Stock | 9,750 | 6.82 | 66.5K | 47,250 | D | ↗ |
| 2026-04-22 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 9,100 | 39.09 | 355.7K | 113,987 | D | ↗ |
| 2026-04-15 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 1,559 | 42.53 | 66.3K | 105,211 | D | ↗ |
| 2026-04-15 | Inrig Jula | Officer | S-Sale | D | Common Stock | 1,018 | 42.61 | 43.4K | 111,473 | D | ↗ |
| 2026-04-15 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 7,165 | 41.75 | 299.1K | 432,906 | D | ↗ |
| 2026-04-15 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 1,014 | 42.61 | 43.2K | 116,899 | D | ↗ |
| 2026-04-14 | REED ELIZABETH E | Officer | M-Exempt | A | Common Stock | 7,500 | 15.46 | 116.0K | 156,711 | D | ↗ |
| 2026-04-14 | LYONS GARY A | Director | S-Sale | D | Common Stock | 8,000 | 41.07 | 328.6K | 57,500 | D | ↗ |
| 2026-04-14 | Inrig Jula | Officer | S-Sale | D | Common Stock | 7,215 | 41.93 | 302.5K | 112,491 | D | ↗ |
| 2026-04-14 | Heerma Peter | Officer | S-Sale | D | Common Stock | 7,215 | 41.93 | 302.5K | 138,608 | D | ↗ |
| 2026-04-14 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 9 | 41.07 | 369.63 | 125,152 | D | ↗ |
| 2026-04-14 | Calvin Sandra | Officer | M-Exempt | A | Common Stock | 6,500 | 20.46 | 133.0K | 64,330 | D | ↗ |
| 2026-04-14 | Baynes Roy D. | Director | M-Exempt | A | Common Stock | 9,000 | 15.43 | 138.9K | 54,500 | D | ↗ |
| 2026-04-13 | ROTE WILLIAM E. | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 123,087 | D | ↗ |
| 2026-04-13 | REED ELIZABETH E | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 119,211 | D | ↗ |
| 2026-04-13 | Inrig Jula | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 119,706 | D | ↗ |
| 2026-04-13 | Heerma Peter | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 145,823 | D | ↗ |
| 2026-04-13 | Dube Eric M | Director / Officer | A-Award | A | Common Stock | 64,000 | 0.00 | — | 496,886 | D | ↗ |
| 2026-04-13 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 65 | 28.85 | 1.9K | 125,161 | D | ↗ |
| 2026-04-06 | Baynes Roy D. | Director | M-Exempt | A | Common Stock | 10,000 | 26.52 | 265.2K | 47,500 | D | ↗ |
| 2026-04-01 | REED ELIZABETH E | Officer | M-Exempt | A | Common Stock | 10,000 | 15.46 | 154.6K | 115,211 | D | ↗ |
| 2026-04-01 | Dube Eric M | Director / Officer | M-Exempt | A | Common Stock | 60,000 | 15.46 | 927.6K | 492,886 | D | ↗ |
| 2026-03-16 | REED ELIZABETH E | Officer | M-Exempt | D | Employee stock option (right to buy) | 10,000 | 19.08 | 190.8K | 10,000 | D | ↗ |
| 2026-02-20 | Dube Eric M | Director / Officer | M-Exempt | A | Common Stock | 60,000 | 15.46 | 927.6K | 492,886 | D | ↗ |
| 2026-02-17 | REED ELIZABETH E | Officer | M-Exempt | A | Common Stock | 10,000 | 19.08 | 190.8K | 115,211 | D | ↗ |
| 2026-02-04 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 2,485 | 32.07 | 79.7K | 105,720 | D | ↗ |
| 2026-02-04 | Inrig Jula | Officer | S-Sale | D | Common Stock | 1,547 | 32.11 | 49.7K | 105,938 | D | ↗ |
| 2026-02-04 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 110 | 32.90 | 3.6K | 111,226 | D | ↗ |
| 2026-02-03 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 12,446 | 32.87 | 409.1K | 109,087 | D | ↗ |
| 2026-02-03 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 7,175 | 32.12 | 230.5K | 108,205 | D | ↗ |
| 2026-02-03 | Inrig Jula | Officer | S-Sale | D | Common Stock | 6,956 | 32.12 | 223.4K | 107,485 | D | ↗ |
| 2026-02-03 | Heerma Peter | Officer | S-Sale | D | Common Stock | 7,310 | 32.12 | 234.8K | 131,823 | D | ↗ |
| 2026-02-03 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 33,635 | 32.70 | 1.10M | 432,886 | D | ↗ |
| 2026-02-03 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 7,242 | 32.12 | 232.6K | 112,971 | D | ↗ |
| 2026-02-03 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 4,333 | 32.12 | 139.2K | 49,080 | D | ↗ |
| 2026-01-31 | ROTE WILLIAM E. | Officer | A-Award | A | Common Stock | 20,090 | 0.00 | — | 121,533 | D | ↗ |
| 2026-01-31 | REED ELIZABETH E | Officer | A-Award | A | Common Stock | 25,110 | 0.00 | — | 115,380 | D | ↗ |
| 2026-01-31 | Inrig Jula | Officer | A-Award | A | Employee stock option (right to buy) | 75,000 | 33.10 | 2.48M | 75,000 | D | ↗ |
| 2026-01-31 | Heerma Peter | Officer | A-Award | A | Employee stock option (right to buy) | 69,640 | 33.10 | 2.30M | 69,640 | D | ↗ |
| 2026-01-31 | Dube Eric M | Director / Officer | A-Award | A | Employee stock option (right to buy) | 303,600 | 33.10 | 10.05M | 303,600 | D | ↗ |
| 2026-01-31 | Cline Christopher R. | Officer | A-Award | A | Employee stock option (right to buy) | 75,000 | 33.10 | 2.48M | 75,000 | D | ↗ |
| 2026-01-31 | Calvin Sandra | Officer | A-Award | A | Employee stock option (right to buy) | 20,160 | 33.10 | 667.2K | 20,160 | D | ↗ |
| 2026-01-27 | Dube Eric M | Director / Officer | M-Exempt | A | Common Stock | 51,865 | 15.46 | 801.8K | 471,038 | D | ↗ |
| 2026-01-23 | Dube Eric M | Director / Officer | M-Exempt | A | Common Stock | 8,135 | 15.46 | 125.8K | 427,308 | D | ↗ |
| 2026-01-20 | REED ELIZABETH E | Officer | M-Exempt | D | Employee stock option (right to buy) | 10,000 | 19.08 | 190.8K | 30,000 | D | ↗ |
| 2026-01-06 | Inrig Jula | Officer | S-Sale | D | Common Stock | 445 | 37.75 | 16.8K | 86,311 | D | ↗ |
| 2026-01-05 | Inrig Jula | Officer | S-Sale | D | Common Stock | 2,031 | 40.18 | 81.6K | 86,756 | D | ↗ |
| 2025-12-24 | ROTE WILLIAM E. | Officer | M-Exempt | D | Employee stock option (right to buy) | 60,000 | 20.61 | 1.24M | 0 | D | ↗ |
| 2025-12-24 | Inrig Jula | Officer | M-Exempt | D | Employee stock option (right to buy) | 15,000 | 8.93 | 134.0K | 76,000 | D | ↗ |
| 2025-12-24 | Heerma Peter | Officer | S-Sale | D | Common Stock | 4,980 | 40.00 | 199.2K | 113,013 | D | ↗ |
| 2025-12-24 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 7,402 | 40.00 | 296.1K | 38,233 | D | ↗ |
| 2025-12-15 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 2,910 | 36.00 | 104.8K | 45,635 | D | ↗ |
| 2025-12-01 | Cline Christopher R. | Officer | M-Exempt | A | Common Stock | 20,000 | 16.23 | 324.6K | 112,083 | D | ↗ |
| 2025-11-04 | Calvin Sandra | Officer | M-Exempt | D | Employee stock option (right to buy) | 15,000 | 27.50 | 412.5K | 2,500 | D | ↗ |
| 2025-11-03 | Heerma Peter | Officer | G-Gift | D | Common Stock | 1,078 | 0.00 | — | 117,993 | D | ↗ |
| 2025-10-31 | Heerma Peter | Officer | S-Sale | D | Common Stock | 5,591 | 35.00 | 195.7K | 119,071 | D | ↗ |
| 2025-10-31 | Coughlin Timothy | Director | M-Exempt | A | Common Stock | 10,000 | 17.44 | 174.4K | 73,500 | D | ↗ |
| 2025-10-29 | Dube Eric M | Director / Officer | M-Exempt | A | Common Stock | 27,128 | 15.46 | 419.4K | 446,301 | D | ↗ |
| 2025-10-28 | Heerma Peter | Officer | S-Sale | D | Common Stock | 2,662 | 30.00 | 79.9K | 124,662 | D | ↗ |
| 2025-10-28 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 92,872 | 30.38 | 2.82M | 419,173 | D | ↗ |
| 2025-09-23 | Heerma Peter | Officer | G-Gift | D | Common Stock | 891 | 0.00 | — | 127,324 | D | ↗ |
| 2025-09-22 | REED ELIZABETH E | Officer | M-Exempt | D | Employee stock option (right to buy) | 10,000 | 19.08 | 190.8K | 40,000 | D | ↗ |
| 2025-09-04 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 119 | 19.71 | 2.3K | 92,083 | D | ↗ |
| 2025-09-03 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 454 | 18.20 | 8.3K | 92,202 | D | ↗ |
| 2025-08-27 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 470 | 17.31 | 8.1K | 92,656 | D | ↗ |
| 2025-07-01 | Inrig Jula | Officer | S-Sale | D | Common Stock | 815 | 14.65 | 11.9K | 88,787 | D | ↗ |
| 2025-05-15 | Williams Brinkley Ruth | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | Squarer Ron | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | Poole Sandra | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | Orwin John A | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | Meckler Jeffrey A | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | LYONS GARY A | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | COUGHLIN TIMOTHY | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | Bruhn Suzanne Louise | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-15 | Baynes Roy D. | Director | A-Award | A | Stock option (right to buy) | 19,500 | 21.15 | 412.4K | 19,500 | D | ↗ |
| 2025-05-05 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 3,198 | 21.05 | 67.3K | 100,241 | D | ↗ |
| 2025-05-05 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 4,920 | 21.05 | 103.6K | 89,482 | D | ↗ |
| 2025-05-05 | Heerma Peter | Officer | S-Sale | D | Common Stock | 1,771 | 21.05 | 37.3K | 128,215 | D | ↗ |
| 2025-05-05 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 18,924 | 21.05 | 398.4K | 419,173 | D | ↗ |
| 2025-05-05 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 1,784 | 21.05 | 37.6K | 93,126 | D | ↗ |
| 2025-05-02 | ROTE WILLIAM E. | Officer | M-Exempt | D | Performance-based restricted stock units | 4,920 | 0.00 | — | 4,920 | D | ↗ |
| 2025-05-02 | REED ELIZABETH E | Officer | M-Exempt | A | Common Stock | 4,920 | 0.00 | — | 94,402 | D | ↗ |
| 2025-05-02 | Heerma Peter | Officer | M-Exempt | D | Performance-based restricted stock units | 4,920 | 0.00 | — | 4,920 | D | ↗ |
| 2025-05-02 | Dube Eric M | Director / Officer | M-Exempt | D | Performance-based restricted stock units | 18,924 | 0.00 | — | 18,924 | D | ↗ |
| 2025-05-02 | Cline Christopher R. | Officer | M-Exempt | D | Performance-based restricted stock units | 4,920 | 0.00 | — | 4,920 | D | ↗ |
| 2025-04-11 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 48 | 13.14 | 630.94 | 89,990 | D | ↗ |
| 2025-02-12 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 5,200 | 23.53 | 122.4K | 98,519 | D | ↗ |
| 2025-02-12 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 8,000 | 23.53 | 188.2K | 89,482 | D | ↗ |
| 2025-02-12 | Inrig Jula | Officer | S-Sale | D | Common Stock | 2,568 | 23.53 | 60.4K | 89,602 | D | ↗ |
| 2025-02-12 | Heerma Peter | Officer | S-Sale | D | Common Stock | 2,568 | 23.53 | 60.4K | 125,066 | D | ↗ |
| 2025-02-11 | Heerma Peter | Officer | S-Sale | D | Common Stock | 3,074 | 25.00 | 76.9K | 127,634 | D | ↗ |
| 2025-02-11 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 11,375 | 24.04 | 273.5K | 419,173 | D | ↗ |
| 2025-02-11 | Calvin Sandra | Officer | M-Exempt | D | Employee stock option (right to buy) | 10,000 | 17.96 | 179.6K | 0 | D | ↗ |
| 2025-02-10 | ROTE WILLIAM E. | Officer | M-Exempt | A | Common Stock | 8,000 | 0.00 | — | 103,719 | D | ↗ |
| 2025-02-10 | REED ELIZABETH E | Officer | M-Exempt | A | Common Stock | 8,000 | 0.00 | — | 97,482 | D | ↗ |
| 2025-02-10 | Inrig Jula | Officer | M-Exempt | D | Performance-based restricted stock units | 8,000 | 0.00 | — | 0 | D | ↗ |
| 2025-02-10 | Heerma Peter | Officer | M-Exempt | D | Performance-based restricted stock units | 8,000 | 0.00 | — | 0 | D | ↗ |
| 2025-02-06 | Baynes Roy D. | Director | M-Exempt | A | Common Stock | 10,000 | 17.44 | 174.4K | 41,000 | D | ↗ |
| 2025-02-04 | Inrig Jula | Officer | S-Sale | D | Common Stock | 1,066 | 20.11 | 21.4K | 84,170 | D | ↗ |
| 2025-02-03 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 8,951 | 19.78 | 177.1K | 95,719 | D | ↗ |
| 2025-02-03 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 8,951 | 19.78 | 177.1K | 89,482 | D | ↗ |
| 2025-02-03 | Inrig Jula | Officer | S-Sale | D | Common Stock | 4,207 | 20.12 | 84.6K | 85,236 | D | ↗ |
| 2025-02-03 | Heerma Peter | Officer | S-Sale | D | Common Stock | 5,166 | 20.12 | 103.9K | 122,708 | D | ↗ |
| 2025-02-03 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 50,691 | 20.21 | 1.02M | 430,548 | D | ↗ |
| 2025-02-03 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 5,192 | 20.12 | 104.5K | 90,038 | D | ↗ |
| 2025-02-03 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 3,348 | 20.12 | 67.4K | 63,654 | D | ↗ |
| 2025-01-31 | ROTE WILLIAM E. | Officer | A-Award | A | Common Stock | 21,500 | 0.00 | — | 104,670 | D | ↗ |
| 2025-01-31 | REED ELIZABETH E | Officer | A-Award | A | Employee stock option (right to buy) | 58,000 | 20.46 | 1.19M | 58,000 | D | ↗ |
| 2025-01-31 | Inrig Jula | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 89,443 | D | ↗ |
| 2025-01-31 | Heerma Peter | Officer | A-Award | A | Employee stock option (right to buy) | 58,000 | 20.46 | 1.19M | 58,000 | D | ↗ |
| 2025-01-31 | Dube Eric M | Director / Officer | A-Award | A | Common Stock | 130,000 | 0.00 | — | 481,239 | D | ↗ |
| 2025-01-31 | Cline Christopher R. | Officer | A-Award | A | Employee stock option (right to buy) | 58,000 | 20.46 | 1.19M | 58,000 | D | ↗ |
| 2025-01-31 | Calvin Sandra | Officer | A-Award | A | Employee stock option (right to buy) | 26,000 | 20.46 | 532.0K | 26,000 | D | ↗ |
| 2025-01-23 | Baynes Roy D. | Director | M-Exempt | A | Common Stock | 16,000 | 17.50 | 280.0K | 47,000 | D | ↗ |
| 2025-01-22 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 2,437 | 19.46 | 47.4K | 83,170 | D | ↗ |
| 2025-01-22 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 2,437 | 19.46 | 47.4K | 76,933 | D | ↗ |
| 2025-01-22 | Heerma Peter | Officer | S-Sale | D | Common Stock | 1,584 | 18.94 | 30.0K | 106,374 | D | ↗ |
| 2025-01-22 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 10,736 | 19.46 | 208.9K | 351,239 | D | ↗ |
| 2025-01-22 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 865 | 18.94 | 16.4K | 73,730 | D | ↗ |
| 2025-01-22 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 925 | 18.94 | 17.5K | 54,002 | D | ↗ |
| 2025-01-06 | Inrig Jula | Officer | S-Sale | D | Common Stock | 440 | 18.76 | 8.3K | 59,443 | D | ↗ |
| 2025-01-03 | Inrig Jula | Officer | S-Sale | D | Common Stock | 2,066 | 19.10 | 39.5K | 59,883 | D | ↗ |
| 2024-12-26 | Calvin Sandra | Officer | M-Exempt | A | Common Stock | 15,000 | 12.67 | 190.1K | 69,927 | D | ↗ |
| 2024-11-25 | Calvin Sandra | Officer | M-Exempt | D | Employee stock option (right to buy) | 15,000 | 12.67 | 190.1K | 15,000 | D | ↗ |
| 2024-10-04 | LYONS GARY A | Director | M-Exempt | A | Common Stock | 40,000 | 10.48 | 419.2K | 91,000 | D | ↗ |
| 2024-09-30 | Meckler Jeffrey A | Director | M-Exempt | A | Common Stock | 40,000 | 10.48 | 419.2K | 121,000 | D | ↗ |
| 2024-09-10 | Inrig Jula | Officer | S-Sale | D | Common Stock | 684 | 12.98 | 8.9K | 61,949 | — | ↗ |
| 2024-09-09 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 4,387 | 11.52 | 50.5K | 84,455 | — | ↗ |
| 2024-09-09 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 4,387 | 11.52 | 50.5K | 78,633 | — | ↗ |
| 2024-09-09 | Inrig Jula | Officer | S-Sale | D | Common Stock | 2,191 | 11.52 | 25.2K | 62,633 | — | ↗ |
| 2024-09-09 | Heerma Peter | Officer | S-Sale | D | Common Stock | 2,191 | 11.52 | 25.2K | 107,958 | — | ↗ |
| 2024-09-09 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 21,125 | 11.52 | 243.4K | 361,975 | — | ↗ |
| 2024-09-09 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 2,490 | 11.52 | 28.7K | 74,595 | — | ↗ |
| 2024-09-05 | ROTE WILLIAM E. | Officer | A-Award | A | Common Stock | 6,750 | 0.00 | — | 88,842 | — | ↗ |
| 2024-09-05 | REED ELIZABETH E | Officer | A-Award | A | Common Stock | 6,750 | 0.00 | — | 83,020 | — | ↗ |
| 2024-09-05 | Inrig Jula | Officer | A-Award | A | Common Stock | 6,750 | 0.00 | — | 64,824 | — | ↗ |
| 2024-09-05 | Heerma Peter | Officer | A-Award | A | Common Stock | 6,750 | 0.00 | — | 110,149 | — | ↗ |
| 2024-09-05 | Dube Eric M | Director / Officer | A-Award | A | Common Stock | 32,500 | 0.00 | — | 383,100 | — | ↗ |
| 2024-09-05 | Cline Christopher R. | Officer | A-Award | A | Common Stock | 6,750 | 0.00 | — | 77,085 | — | ↗ |
| 2024-09-04 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 514 | 9.51 | 4.9K | 70,335 | — | ↗ |
| 2024-05-08 | Williams Brinkley Ruth | Director | A-Award | A | Common Stock | 6,500 | 0.00 | — | 19,250 | — | ↗ |
| 2024-05-08 | Squarer Ron | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-05-08 | Poole Sandra | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-05-08 | Orwin John A | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-05-08 | Meckler Jeffrey A | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-05-08 | LYONS GARY A | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-05-08 | COUGHLIN TIMOTHY | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-05-08 | Bruhn Suzanne Louise | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-05-08 | Baynes Roy D. | Director | A-Award | A | Stock option (right to buy) | 19,500 | 6.82 | 133.0K | 19,500 | — | ↗ |
| 2024-04-11 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 54 | 6.74 | 363.96 | 70,849 | — | ↗ |
| 2024-02-01 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 2,590 | 8.86 | 22.9K | 80,720 | — | ↗ |
| 2024-02-01 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 2,590 | 8.86 | 22.9K | 76,270 | — | ↗ |
| 2024-02-01 | Inrig Jula | Officer | S-Sale | D | Common Stock | 2,174 | 8.53 | 18.5K | 58,074 | — | ↗ |
| 2024-02-01 | Heerma Peter | Officer | S-Sale | D | Common Stock | 4,195 | 8.53 | 35.8K | 99,503 | — | ↗ |
| 2024-02-01 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 10,016 | 8.86 | 88.7K | 350,600 | — | ↗ |
| 2024-02-01 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 3,818 | 8.53 | 32.6K | 70,903 | — | ↗ |
| 2024-02-01 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 2,820 | 8.53 | 24.1K | 52,017 | — | ↗ |
| 2024-01-31 | ROTE WILLIAM E. | Officer | A-Award | A | Employee stock option (right to buy) | 65,000 | 8.93 | 580.5K | 65,000 | — | ↗ |
| 2024-01-31 | REED ELIZABETH E | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 81,034 | — | ↗ |
| 2024-01-31 | Inrig Jula | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 60,248 | — | ↗ |
| 2024-01-31 | Heerma Peter | Officer | A-Award | A | Employee stock option (right to buy) | 65,000 | 8.93 | 580.5K | 65,000 | — | ↗ |
| 2024-01-31 | Dube Eric M | Director / Officer | A-Award | A | Employee stock option (right to buy) | 360,000 | 8.93 | 3.21M | 360,000 | — | ↗ |
| 2024-01-31 | Cline Christopher R. | Officer | A-Award | A | Employee stock option (right to buy) | 65,000 | 8.93 | 580.5K | 65,000 | — | ↗ |
| 2024-01-31 | Calvin Sandra | Officer | A-Award | A | Common Stock | 1,000 | 0.00 | — | 54,837 | — | ↗ |
| 2024-01-23 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 2,062 | 8.96 | 18.5K | 60,484 | — | ↗ |
| 2024-01-23 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 2,062 | 8.96 | 18.5K | 56,034 | — | ↗ |
| 2024-01-23 | Heerma Peter | Officer | S-Sale | D | Common Stock | 1,559 | 9.07 | 14.1K | 78,698 | — | ↗ |
| 2024-01-23 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 7,873 | 8.96 | 70.5K | 234,722 | — | ↗ |
| 2024-01-23 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 853 | 9.07 | 7.7K | 49,721 | — | ↗ |
| 2024-01-23 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 910 | 9.07 | 8.3K | 41,337 | — | ↗ |
| 2024-01-04 | Inrig Jula | Officer | S-Sale | D | Common Stock | 440 | 9.17 | 4.0K | 35,248 | — | ↗ |
| 2024-01-03 | Inrig Jula | Officer | S-Sale | D | Common Stock | 2,069 | 9.48 | 19.6K | 35,688 | — | ↗ |
| 2023-10-03 | Heerma Peter | Officer | S-Sale | D | Common Stock | 3,091 | 8.25 | 25.5K | 80,257 | — | ↗ |
| 2023-09-05 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 1,815 | 14.71 | 26.7K | 61,173 | — | ↗ |
| 2023-09-05 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 1,815 | 14.71 | 26.7K | 58,096 | — | ↗ |
| 2023-09-05 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 4,455 | 14.71 | 65.5K | 242,595 | — | ↗ |
| 2023-09-05 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 457 | 14.71 | 6.7K | 50,574 | — | ↗ |
| 2023-08-31 | ROTE WILLIAM E. | Officer | A-Award | A | Common Stock | 3,300 | 0.00 | — | 62,988 | — | ↗ |
| 2023-08-31 | REED ELIZABETH E | Officer | A-Award | A | Common Stock | 3,300 | 0.00 | — | 59,911 | — | ↗ |
| 2023-08-31 | Dube Eric M | Director / Officer | A-Award | A | Common Stock | 9,900 | 0.00 | — | 247,050 | — | ↗ |
| 2023-05-17 | Williams Brinkley Ruth | Director | A-Award | A | Common Stock | 4,500 | 0.00 | — | 12,750 | — | ↗ |
| 2023-05-17 | Squarer Ron | Director | A-Award | A | Common Stock | 4,500 | 0.00 | — | 22,375 | — | ↗ |
| 2023-05-17 | Poole Sandra | Director | A-Award | A | Stock option (right to buy) | 13,500 | 17.11 | 231.0K | 13,500 | — | ↗ |
| 2023-05-17 | Orwin John A | Director | A-Award | A | Stock option (right to buy) | 13,500 | 17.11 | 231.0K | 13,500 | — | ↗ |
| 2023-05-17 | Meckler Jeffrey A | Director | A-Award | A | Common Stock | 4,500 | 0.00 | — | 74,500 | — | ↗ |
| 2023-05-17 | LYONS GARY A | Director | A-Award | A | Stock option (right to buy) | 13,500 | 17.11 | 231.0K | 13,500 | — | ↗ |
| 2023-05-17 | COUGHLIN TIMOTHY | Director | A-Award | A | Stock option (right to buy) | 13,500 | 17.11 | 231.0K | 13,500 | — | ↗ |
| 2023-05-17 | Bruhn Suzanne Louise | Director | A-Award | A | Stock option (right to buy) | 13,500 | 17.11 | 231.0K | 13,500 | — | ↗ |
| 2023-05-17 | Baynes Roy D. | Director | A-Award | A | Stock option (right to buy) | 13,500 | 17.11 | 231.0K | 13,500 | — | ↗ |
| 2023-05-11 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 122 | 16.12 | 2.0K | 42,247 | — | ↗ |
| 2023-05-10 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 825 | 16.59 | 13.7K | 59,211 | — | ↗ |
| 2023-05-10 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 825 | 16.59 | 13.7K | 56,611 | — | ↗ |
| 2023-05-10 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 455 | 16.59 | 7.5K | 51,031 | — | ↗ |
| 2023-05-10 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 436 | 16.59 | 7.2K | 42,369 | — | ↗ |
| 2023-04-11 | Cline Christopher R. | Officer | S-Sale | D | Common Stock | 47 | 21.49 | 1.0K | 51,486 | — | ↗ |
| 2023-02-02 | Calvin Sandra | Officer | S-Sale | D | Common Stock | 360 | 22.42 | 8.1K | 42,805 | — | ↗ |
| 2023-02-01 | ROTE WILLIAM E. | Officer | S-Sale | D | Common Stock | 2,590 | 22.25 | 57.6K | 60,036 | — | ↗ |
| 2023-02-01 | REED ELIZABETH E | Officer | S-Sale | D | Common Stock | 2,590 | 22.25 | 57.6K | 57,436 | — | ↗ |
| 2023-02-01 | Heerma Peter | Officer | S-Sale | D | Common Stock | 1,779 | 21.75 | 38.7K | 82,069 | — | ↗ |
| 2023-02-01 | Dube Eric M | Director / Officer | S-Sale | D | Common Stock | 8,196 | 22.25 | 182.4K | 237,150 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-100.1K
Shares Outstanding
92.37M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Eric Dube, Ph.D. President, Chief Executive Officer and Director | 854.3K | — | 3.31M | 3.31M | 964.1K | 14.9K | 8.46M | 78.32% | ↗ |
| 2 | 2025 | Jula Inrig, M.D. Chief Medical Officer | 568.1K | — | 757.0K | 1.27M | 429.0K | 14.7K | 3.04M | 66.74% | ↗ |
| 3 | 2025 | Peter Heerma Chief Commercial Officer | 527.9K | — | 583.1K | 738.2K | 397.5K | 15.0K | 2.26M | 58.42% | ↗ |
| 4 | 2025 | William E. Rote, Ph.D. Chief Research Officer | 522.3K | — | 583.1K | 738.2K | 393.0K | 19.8K | 2.26M | 58.56% | ↗ |
| 5 | 2025 | Christopher Cline Chief Financial Officer | 522.9K | — | 583.1K | 738.2K | 393.8K | 12.9K | 2.25M | 58.70% | ↗ |
| 6 | 2024 | Eric Dube, Ph.D. President, Chief Executive Officer and Director | 822.0K | — | 1.61M | 1.90M | 865.2K | 14.7K | 5.20M | 67.30% | ↗ |
| 7 | 2024 | Jula Inrig, M.D. Chief Medical Officer | 522.1K | — | 299.2K | 479.2K | 367.5K | 13.4K | 1.68M | 46.29% | ↗ |
| 8 | 2024 | William E. Rote, Ph.D. Chief Research Officer | 502.8K | — | 299.2K | 342.3K | 352.8K | 19.6K | 1.52M | 42.29% | ↗ |
| 9 | 2024 | Peter Heerma Chief Commercial Officer | 503.8K | — | 299.2K | 342.3K | 353.5K | 14.7K | 1.51M | 42.38% | ↗ |
| 10 | 2024 | Christopher Cline Chief Financial Officer | 497.5K | — | 299.2K | 342.3K | 350.0K | 12.6K | 1.50M | 42.72% | ↗ |
| 11 | 2023 | Eric Dube, Ph.D. President, Chief Executive Officer and Director | 795.8K | — | 3.04M | 3.13M | 588.0K | 15.4K | 7.57M | 81.53% | ↗ |
| 12 | 2023 | William E. Rote, Ph.D. Senior Vice President and Head of Research and Development | 488.4K | — | 648.3K | 656.7K | 240.1K | 19.5K | 2.05M | 63.57% | ↗ |
| 13 | 2023 | William E. Rote, Ph.D. Chief Research Officer | 488.4K | — | 648.3K | 656.7K | 240.1K | 19.5K | 2.05M | 63.57% | ↗ |
| 14 | 2023 | Elizabeth Reed Senior Vice President and General Council | 468.4K | — | 648.3K | 656.7K | 230.3K | 14.9K | 2.02M | 64.65% | ↗ |
| 15 | 2023 | Peter Heerma Chief Commercial Officer | 487.2K | — | 604.8K | 656.7K | 240.1K | 15.1K | 2.00M | 62.95% | ↗ |
| 16 | 2023 | Jula Inrig, M.D. Chief Medical Officer | 486.3K | — | 604.8K | 656.7K | 240.1K | 13.6K | 2.00M | 63.03% | ↗ |
| 17 | 2023 | Christopher Cline Chief Financial Officer | 466.7K | — | 604.8K | 656.7K | 230.3K | 13.0K | 1.97M | 63.99% | ↗ |
| 18 | 2022 | Eric Dube, Ph.D. President, Chief Executive Officer and Director | 746.7K | — | 2.08M | 2.32M | 590.6K | 13.0K | 5.75M | 76.53% | ↗ |
| 19 | 2022 | Jula Inrig, M.D. Chief Medical Officer | 445.0K | 125.0K | 832.0K | 1.22M | 233.6K | 12.3K | 2.87M | 71.54% | ↗ |
| 20 | 2022 | Christopher Cline Chief Financial Officer | 397.2K | — | 671.3K | 1.02M | 225.8K | 11.4K | 2.33M | 72.72% | ↗ |
| 21 | 2022 | William E. Rote, Ph.D. Senior Vice President and Head of Research and Development | 470.2K | — | 761.2K | 538.9K | 247.3K | 15.8K | 2.03M | 63.94% | ↗ |
| 22 | 2022 | William E. Rote, Ph.D. Chief Research Officer | 470.2K | — | 761.2K | 538.9K | 247.3K | 15.8K | 2.03M | 63.94% | ↗ |
| 23 | 2022 | Peter Heerma Chief Commercial Officer | 453.2K | — | 761.2K | 538.9K | 239.4K | 13.0K | 2.01M | 64.82% | ↗ |
| 24 | 2022 | Elizabeth Reed Senior Vice President and General Council | 449.1K | — | 761.2K | 538.9K | 236.8K | 12.5K | 2.00M | 65.05% | ↗ |
| 25 | 2022 | Laura Clague Former Chief Financial Officer | 422.5K | — | 761.2K | 538.9K | 222.6K | 18.1K | 1.96M | 66.22% | ↗ |
| 26 | 2021 | Eric Dube, Ph.D. President, Chief Executive Officer and Director | 708.0K | — | 1.54M | 2.93M | 553.8K | 11.9K | 5.74M | 77.81% | ↗ |
| 27 | 2021 | Noah Rosenberg, M.D. Former Chief Medical Officer | 507.8K | — | 403.2K | 791.2K | — | 1.08M | 2.78M | 42.95% | ↗ |
| 28 | 2021 | William E. Rote, Ph.D. Senior Vice President and Head of Research and Development | 460.9K | — | 403.2K | 791.2K | 276.9K | 14.6K | 1.95M | 61.35% | ↗ |
| 29 | 2021 | Laura Clague Former Chief Financial Officer | 452.1K | — | 403.2K | 791.2K | 271.6K | 16.6K | 1.93M | 61.74% | ↗ |
| 30 | 2021 | Laura Clague Senior Vice President and Chief Financial Officer | 452.1K | — | 403.2K | 791.2K | 271.6K | 16.6K | 1.93M | 61.74% | ↗ |
| 31 | 2021 | Elizabeth Reed Senior Vice President and General Council | 427.9K | — | 403.2K | 791.2K | 257.1K | 11.7K | 1.89M | 63.16% | ↗ |
| 32 | 2021 | Elizabeth Reed Senior Vice President, General Counsel and Corporate Secretary | 427.9K | — | 403.2K | 791.2K | 257.1K | 11.7K | 1.89M | 63.16% | ↗ |
| 33 | 2021 | Peter Heerma Chief Commercial Officer | 421.7K | — | 403.2K | 791.2K | 253.4K | 11.5K | 1.88M | 63.50% | ↗ |
| 34 | 2020 | Eric Dube, Ph.D. President, Chief Executive Officer and Director | 660.9K | — | 1.55M | 2.77M | 457.1K | 11.7K | 5.45M | 79.26% | ↗ |
| 35 | 2020 | William E. Rote, Ph.D. Senior Vice President and Head of Research and Development | 447.5K | — | 432.9K | 508.2K | 254.8K | 14.3K | 1.66M | 56.77% | ↗ |
| 36 | 2020 | Noah Rosenberg, M.D. Chief Medical Officer | 447.0K | — | 432.9K | 508.2K | 254.6K | 12.4K | 1.66M | 56.86% | ↗ |
| 37 | 2020 | Noah Rosenberg, M.D. Former Chief Medical Officer | 447.0K | — | 432.9K | 508.2K | 254.6K | 12.4K | 1.66M | 56.86% | ↗ |
| 38 | 2020 | Laura Clague Former Chief Financial Officer | 436.8K | — | 432.9K | 508.2K | 254.2K | 16.6K | 1.65M | 57.08% | ↗ |
| 39 | 2020 | Laura Clague Senior Vice President and Chief Financial Officer | 436.8K | — | 432.9K | 508.2K | 254.2K | 16.6K | 1.65M | 57.08% | ↗ |
| 40 | 2020 | Elizabeth Reed Senior Vice President, General Counsel and Corporate Secretary | 413.4K | — | 432.9K | 508.2K | 235.5K | 11.2K | 1.60M | 58.77% | ↗ |
| 41 | 2020 | Peter Heerma Chief Commercial Officer | 407.7K | 87.5K | 278.3K | 508.2K | 232.1K | 18.6K | 1.53M | 51.33% | ↗ |
| 42 | 2019 | Eric Dube, Ph.D. President, Chief Executive Officer and Director | 618.2K | 100.0K | 2.44M | 5.98M | 337.5K | 204.6K | 9.68M | 86.98% | ↗ |
| 43 | 2019 | Noah Rosenberg, M.D. Chief Medical Officer | 432.1K | — | 215.5K | 453.0K | 195.1K | 74.0K | 1.37M | 48.81% | ↗ |
| 44 | 2019 | Noah Rosenberg, M.D. Former Chief Medical Officer | 432.1K | — | 215.5K | 453.0K | 195.1K | 74.0K | 1.37M | 48.81% | ↗ |
| 45 | 2019 | Peter Heerma Chief Commercial Officer | 100.0K | 87.5K | 393.8K | 695.1K | 46.3K | 2.6K | 1.33M | 82.16% | ↗ |
| 46 | 2019 | William E. Rote, Ph.D. Senior Vice President and Head of Research and Development | 432.9K | — | 215.5K | 453.0K | 195.7K | 13.1K | 1.31M | 51.02% | ↗ |
| 47 | 2019 | Laura Clague Senior Vice President and Chief Financial Officer | 419.3K | — | 215.5K | 453.0K | 200.7K | 15.0K | 1.30M | 51.28% | ↗ |
| 48 | 2019 | Elizabeth Reed Senior Vice President, General Counsel and Corporate Secretary | 391.7K | — | 215.5K | 453.0K | 187.5K | 10.8K | 1.26M | 53.12% | ↗ |
| 49 | 2019 | Stephen Aselage Director and Former President and Chief Executive Officer | 76.2K | — | — | — | — | 963.1K | 1.04M | 0.00% | ↗ |
| 50 | 2018 | Stephen Aselage Director and Former President and Chief Executive Officer | 593.3K | — | 1.31M | 2.36M | 331.2K | 8.3K | 4.60M | 79.73% | ↗ |
| 51 | 2018 | Stephen Aselage President and Chief Executive Officer | 593.3K | — | 1.31M | 2.36M | 331.2K | 8.3K | 4.60M | 79.73% | ↗ |
| 52 | 2018 | Noah Rosenberg, M.D. Chief Medical Officer | 183.6K | 100.0K | 571.6K | 1.18M | 97.8K | 266.5K | 2.40M | 73.04% | ↗ |
| 53 | 2018 | Neil McFarlane Chief Operating Officer | 494.2K | — | 584.5K | 1.01M | 228.4K | 27.9K | 2.35M | 67.99% | ↗ |
| 54 | 2018 | Laura Clague Senior Vice President and Chief Financial Officer | 399.6K | — | 497.8K | 769.5K | 185.2K | 8.3K | 1.86M | 68.12% | ↗ |
| 55 | 2018 | William E. Rote, Ph.D. Senior Vice President and Head of Research and Development | 420.3K | — | 370.5K | 625.2K | 194.3K | 8.3K | 1.62M | 61.52% | ↗ |
| 56 | 2018 | Elizabeth Reed Senior Vice President, General Counsel and Corporate Secretary | 347.5K | — | 391.2K | 673.3K | 161.0K | 8.3K | 1.58M | 67.32% | ↗ |
| 57 | 2017 | Stephen Aselage Director and Former President and Chief Executive Officer | 552.6K | — | 795.0K | 1.85M | 226.8K | 8.1K | 3.43M | 77.03% | ↗ |
| 58 | 2017 | Stephen Aselage President, Chief Executive Officer and Director | 552.6K | — | 795.0K | 1.85M | 226.8K | 8.1K | 3.43M | 77.03% | ↗ |
| 59 | 2017 | Stephen Aselage President and Chief Executive Officer | 552.6K | — | 795.0K | 1.85M | 226.8K | 8.1K | 3.43M | 77.03% | ↗ |
| 60 | 2017 | Neil McFarlane Chief Operating Officer | 480.9K | — | 442.3K | 1.01M | 162.7K | 94.2K | 2.19M | 66.26% | ↗ |
| 61 | 2017 | William E. Rote, Ph.D. Senior Vice President and Head of Research and Development | 363.5K | — | 557.5K | 797.7K | 126.8K | 8.1K | 1.85M | 73.11% | ↗ |
| 62 | 2017 | Elizabeth E. Reed Senior Vice President, General Counsel and Corporate Secretary | 331.3K | — | 514.7K | 615.4K | 113.1K | 8.0K | 1.58M | 71.41% | ↗ |
| 63 | 2017 | Laura Clague Senior Vice President and Chief Financial Officer | 382.5K | — | 304.9K | 671.2K | 129.9K | 8.1K | 1.50M | 65.22% | ↗ |
| 64 | 2016 | Stephen Aselage President and Chief Executive Officer | 510.4K | — | 649.2K | 1.57M | 263.4K | 8.0K | 3.00M | 73.93% | ↗ |
| 65 | 2016 | Stephen Aselage President, Chief Executive Officer and Director | 510.4K | — | 649.2K | 1.57M | 263.4K | 8.0K | 3.00M | 73.93% | ↗ |
| 66 | 2016 | Neil McFarlane Chief Operating Officer | 180.0K | 100.0K | 792.9K | 1.27M | 84.1K | 3.1K | 2.43M | 84.90% | ↗ |
| 67 | 2016 | Margaret Valeur-Jensen, Ph.D. Former General Counsel | 435.7K | — | 782.5K | — | 186.1K | 50.5K | 1.45M | 53.79% | ↗ |
| 68 | 2016 | Laura Clague Senior Vice President and Chief Financial Officer | 368.0K | — | 243.5K | 587.9K | 157.2K | 8.0K | 1.36M | 60.93% | ↗ |
| 69 | 2016 | Laura Clague Chief Financial Officer | 368.0K | — | 243.5K | 587.9K | 157.2K | 8.0K | 1.36M | 60.93% | ↗ |
| 70 | 2016 | Alvin Shih, M.D. Former Executive Vice President of Research and Development | 428.1K | — | 243.5K | 587.9K | — | — | 1.26M | 66.01% | ↗ |
| 71 | 2015 | Stephen Aselage, President, Chief Executive Officer and Director | 480.0K | — | 1.20M | 3.45M | 302.4K | — | 5.44M | 85.61% | ↗ |
| 72 | 2015 | Stephen Aselage President, Chief Executive Officer and Director | 480.0K | — | 1.20M | 3.45M | 302.4K | — | 5.44M | 85.61% | ↗ |
| 73 | 2015 | Alvin Shih, M.D. Former Executive Vice President of Research and Development | 450.0K | — | 487.4K | 1.38M | 234.0K | — | 2.55M | 73.20% | ↗ |
| 74 | 2015 | Alvin Shih, M.D. Executive Vice President of Research and Development | 450.0K | — | 487.4K | 1.38M | 234.0K | — | 2.55M | 73.20% | ↗ |
| 75 | 2015 | Margaret Valeur-Jensen, Ph.D., General Counsel | 425.0K | — | 487.4K | 1.38M | 221.0K | — | 2.51M | 74.31% | ↗ |
| 76 | 2015 | Margaret Valeur-Jensen, Ph.D. Former General Counsel | 425.0K | — | 487.4K | 1.38M | 221.0K | — | 2.51M | 74.31% | ↗ |
| 77 | 2015 | Laura Clague, Chief Financial Officer | 353.0K | — | 487.4K | 1.38M | 186.7K | — | 2.41M | 77.59% | ↗ |
| 78 | 2015 | Laura Clague Senior Vice President and Chief Financial Officer | 353.0K | — | 487.4K | 1.38M | 186.7K | — | 2.41M | 77.59% | ↗ |
| 79 | 2015 | Laura Clague Chief Financial Officer | 353.0K | — | 487.4K | 1.38M | 186.7K | — | 2.41M | 77.59% | ↗ |
| 80 | 2014 | Stephen Aselage President, Chief Executive Officer and Director | 202.2K | — | 1.01M | 7.21M | 121.0K | 12.5K | 8.55M | 96.07% | ↗ |
| 81 | 2014 | Stephen Aselage, President, Chief Executive Officer and Director | 202.2K | — | 1.01M | 7.21M | 121.0K | 12.5K | 8.55M | 96.07% | ↗ |
| 82 | 2014 | Stephen Aselage, Director | 202.2K | — | 1.01M | 7.21M | — | 12.5K | 8.43M | 97.45% | ↗ |
| 83 | 2014 | Martin Shkreli, Former Chief Executive Officer | 237.5K | 300.0K | — | 7.60M | — | 62.5K | 8.20M | 92.68% | ↗ |
| 84 | 2014 | Alvin Shih, M.D. Executive Vice President of Research and Development | 262.5K | 50.0K | 3.17M | — | 118.3K | — | 3.60M | 88.02% | ↗ |
| 85 | 2014 | Alvin Shih, M.D. Former Executive Vice President of Research and Development | 262.5K | 50.0K | 3.17M | — | 118.3K | — | 3.60M | 88.02% | ↗ |
| 86 | 2014 | Marc Panoff, Former Chief Financial Officer | 269.4K | 76.7K | 1.90M | — | — | — | 2.25M | 84.59% | ↗ |
| 87 | 2014 | Margaret Valeur-Jensen, Ph.D., General Counsel | 70.8K | 25.0K | 945.0K | — | — | — | 1.04M | 90.79% | ↗ |
| 88 | 2014 | Margaret Valeur-Jensen, Ph.D. Former General Counsel | 70.8K | 25.0K | 945.0K | — | — | — | 1.04M | 90.79% | ↗ |
| 89 | 2014 | Laura Clague Chief Financial Officer | 41.9K | 25.0K | — | 669.0K | — | — | 735.9K | 90.91% | ↗ |
| 90 | 2014 | Laura Clague, Chief Financial Officer | 41.9K | 25.0K | — | 669.0K | — | — | 735.9K | 90.91% | ↗ |
| 91 | 2013 | Martin Shkreli, Former Chief Executive Officer | 252.1K | 1.23M | — | 9.93M | — | — | 11.41M | 86.98% | ↗ |
| 92 | 2013 | Martin Shkreli, Chief Executive Officer | 252.1K | 1.23M | — | 529.2K | — | — | 2.01M | 26.27% | ↗ |
| 93 | 2013 | Horacio Plotkin, Chief Medical Officer | 222.7K | 136.7K | — | 170.5K | — | — | 529.9K | 32.18% | ↗ |
| 94 | 2013 | Marc Panoff, Chief Financial Officer | 142.2K | 104.2K | 157.8K | — | — | — | 404.1K | 39.05% | ↗ |
| 95 | 2013 | Marc Panoff, Former Chief Financial Officer | 142.2K | 104.2K | 157.8K | — | — | — | 404.1K | 39.05% | ↗ |
| 96 | 2013 | Gary Lyons, former Director | — | — | — | — | — | — | — | — | ↗ |
| 97 | 2013 | Stephen Aselage, Director | — | — | — | — | — | — | — | — | ↗ |
| 98 | 2013 | Robert Wilson, former Chief Executive Officer, | — | — | — | — | — | — | — | — | ↗ |
| 99 | 2012 | Martin Shkreli, Chief Executive Officer | 250.0K | 565.2K | 14.44M | — | — | — | 15.26M | 94.66% | ↗ |
| 100 | 2012 | Stephen Aselage, Director | 83.3K | — | 2.00M | — | — | — | 2.08M | 96.00% | ↗ |
| 101 | 2012 | Gary Lyons, former Director | — | — | — | — | — | — | — | — | ↗ |
| 102 | 2012 | Horacio Plotkin, Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 103 | 2012 | Marc Panoff, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 104 | 2012 | Robert Wilson, former Chief Executive Officer, | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eric Dube | President, Chief Executive Officer & Director | 2M | — |
| Jula Inrig | Chief Medical Officer | 1M | — |
| Peter Heerma | Chief Commercial Officer | 940.4K | male |
| William E. Rote | Chief Research Officer | 935.1K | — |
| Christopher Cline | Chief Financial Officer | 929.6K | male |
| Elizabeth E. Reed | Chief Legal Officer, General Counsel & Secretary | 713.6K | female |
| Casey Logan | Chief Business Officer | — | male |
| Sandra Calvin | SVP, Corporate Controller & Chief Accounting Officer | — | female |
| Angela Giannantonio | Chief People Officer | — | female |
| Nivi Nehra | Vice President of Corporate Communications & Investor Relations | — | female |
| Charlotte Smith | Chief Corporate Affairs Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TVTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
